SCHEMBL1324537

SCHEMBL1324537

COC(=O)c1cc(Cl)c2ccnn2c1-c1cccc(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 3/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CSNK1D P48730 2/20 0.38
RPS6KB1 P23443 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
NTRK2 Q16620 1/20 0.38
AURKB Q96GD4 1/20 0.38
PDE4B Q07343 3/20 0.38
SCN9A Q15858 1/20 0.38
NR4A2 P43354 1/20 0.37
ALOX15 P16050 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1324832 0.87 PDE4B (0.39) PDE4BSCN9ACREBBPPDE4APDE4C
SCHEMBL1324522 0.86 KDM4C (0.43) ALDH1A1KDM4ESMN1; SMN2PDE4BNR4A2
SCHEMBL1325440 0.85 TRPM8 (0.45) PDE4BSCN9APDE4APDE4CPDE4D
SCHEMBL12285065 0.84 GRIN2B (0.35) ALDH1A1KDM4EMAPK1PDE4BSCN9A
SCHEMBL1325630 0.80 LCK (0.43) MAPK14ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL18816898 0.79 CSNK1D (0.39) MAPK14ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL1325638 0.78 MAPK14 (0.39) MAPK14ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL1325693 0.77 ALDH1A1 (0.40) MAPK14ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL1325820 0.74 PTGS2 (0.33) ALDH1A1KDM4EMAPK1PDE4BGRIN2B
SCHEMBL1325258 0.72 MAPK14 (0.44) MAPK14ALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 US disclosed
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 US disclosed
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 US disclosed
EP-2558463-A1 FUSED DERIVATIVES AS I3 INHIBITORS Incyte Corporation (US) 2013-02-20 EP disclosed
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS INCYTE CORPORATION 2011-11-17 US disclosed
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS INCYTE CORPORATION 2011-11-17 US disclosed
WO-2011130342-A1 FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS INCYTE CORPORATION (US) 2011-10-20 WO disclosed
WO-2011130342-A1 FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS INCYTE CORPORATION (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS PIK3CD, PIK3CA, PIK3CB MAPK14 603/4885ALDH1A1 4465/4885KDM4E 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.